DelveInsight’s, “HR Positive/ HER2 Negative Breast Cancer-Pipeline Insights, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in HR Positive/ HER2 Negative Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
HR Positive/ HER2 Negative Breast Cancer: Overview
HER2 is also known to be as ERBB2 which is Erb-B2 receptor tyrosine kinase 2. HER2 or ERBB2, is human epidermal growth factor receptor 2 which plays an important role in view of breast cancer. HER2 or ERBB2 gene is responsible for coding HER2 or ERBB2 proteins which are the receptors on the breast. A HER2-negative diagnosis also means that your cancer won't benefit from therapies that target the HER2 protein. Roughly half of metastatic breast cancers are both HR-positive and HER2-negative
Some of the common symptoms of Her2 negative breast cancer:
Three common test employed to test for HER2 levels are chromogenic in situ hybridization (CISH), immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH). Depending on the levels of HER2 or ERBB2 in the laboratory test breast cancer is classified as HER2 or ERBB2 positive or HER2 negative breast cancer. In HER2 or ERBB2 receptors in a normal breast maintains growth, division and repairing while in HER2 or ERBB2 positive breast cancer over-expression of HER2 or ERBB2 is seen. In case of HER2 negative breast cancer the levels of HER2 protein is in normal.
As the HR positive breast cancer mostly affects women. The treatment management of this specific cancer is complex and patient-centric, as treatment and outcomes differ significantly according to biomarker status among other patient characteristics, indicating a trend towards higher personalized medicine based upon patient biomarkers and physiologic characteristics. The treatment for HER2 negative breast cancer includes chemotherapy, radiation, surgery and hormonal or endocrine therapy. Hormonal or endocrine therapy is generally an adjunct therapy given to patients after surgery, chemotherapy or radiation therapy. For treatment of breast cancer receptor testing plays an important role for deciding the treatment for the patient. HER2 negative breast cancer can be ER (Estrogen Receptor) positive if it is tested positive for estrogen receptors; PR (Progesterone Receptor) positive if it is tested positive for progesterone receptor; while breast cancer can be TNBC (Triple Negative Breast Cancer) if there is absence of all three receptors i.e. HER2 or ERBB2, estrogen and progesterone. Generally hormonal therapy is employed for HER2 negative breast cancer.
This segment of the HR Positive/ HER2 Negative Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated for the treatment of HER2 Negative Breast Cancer. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene’s investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies.
The company is developing the drug as a monotherapy and also, as a combination therapy with palbociclib for the treatment of HER2 Negative Breast Cancer. The drug is in phase II stage of development.
H3B 6545 is an orally available, selective estrogen receptor alpha covalent antagonist, being developed by H3 Biomedicine for the treatment of breast cancer.
Further product details are provided in the report……..
This segment of the report provides insights about the different HR Positive/ HER2 Negative Breast Cancer drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 50+ key companies which are developing the therapies for HR Positive/ HER2 Negative Breast Cancer. The companies which have their HR Positive/ HER2 Negative Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, Nightstar Therapeutics/Biogen.
Phases
DelveInsight’s report covers around 50+ products under different phases of clinical development like
HR Positive/ HER2 Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses HR Positive/ HER2 Negative Breast Cancer therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HR Positive/ HER2 Negative Breast Cancer drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
HR Positive/ HER2 Negative Breast Cancer: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
HR Positive/ HER2 Negative Breast Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• HR Positive/ HER2 Negative Breast Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
HR Positive/ HER2 Negative Breast Cancer Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
ANG-1005: Angiochem
• Product Description
• Research and Development
• Product Development Activities
Mid Stage Products (Phase II)
• Comparative Analysis
BGB-290: BeiGene
• Product Description
• Research and Development
• Product Development Activities
Palbociclib: AstraZeneca
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
D 0502: InventisBio
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
HR Positive/ HER2 Negative Breast Cancer Key Companies
HR Positive/ HER2 Negative Breast Cancer Key Products
HR Positive/ HER2 Negative Breast Cancer- Unmet Needs
HR Positive/ HER2 Negative Breast Cancer- Market Drivers and Barriers
HR Positive/ HER2 Negative Breast Cancer- Future Perspectives and Conclusion
HR Positive/ HER2 Negative Breast Cancer Analyst Views
HR Positive/ HER2 Negative Breast Cancer Key Companies
Appendix
List of Tables
Table 1 Total Products for HR Positive/ HER2 Negative Breast Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for HR Positive/ HER2 Negative Breast Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
• Sanofi
• BeiGene
• Olema Pharmaceuticals
• AstraZeneca
• Radius Pharmaceuticals
• H3 Biomedicine
• Novartis Pharmaceuticals
• InventisBio
• Hoffmann-La Roche
• Eli Lilly and Company
• Tesaro, Inc.
• Angiochem
• Amgen
• H3 Biomedicine
• BioMarin Pharmaceutical
• Eagle Pharmaceuticals
• Millennium Pharmaceuticals
• Merck Sharp & Dohme Corp
